Donate

Bladder Cancer Translational Clinical Trial Award

Early Phase Patient-Oriented Research to Reduce the Burden of Bladder Cancer Care and Treatment

In March of 2023, BCAN announced the awardees of the 2022 Translational Clinical Trial Award (TCTA), which supports early-phase patient-oriented research to revolutionize bladder cancer care. The award attracted insightful proposals that addressed innovative methods to alleviate the burden of care and overtreatment for bladder cancer patients across the entire spectrum of patient care, including bladder cancer screening, diagnosis, and treatment of early and advanced stages.

Awardees and their projects have been selected, marking a significant step toward advancing the field of bladder cancer research. We extend our heartfelt congratulations to the accomplished investigators and collaborative study teams who demonstrated excellence in their endeavors.

The awardees of the 2022 Translational Clinical Trial Award are:

Amir Horowitz, Ph.D., Assistant Professor of Oncological Sciences at Icahn School of Medicine at Mount Sinai

Project Title: “Targeting HLA-E/NKG2A for overcoming BCG resistance in non-muscle-invasive bladder cancer”  

Sarah Psutka, MD

Sarah Psutka, MD, MS, Associate Professor of Urology at the University of Washington

Project Title: “The “Get Moving Trial”: A Phase I/II RCT of a Home-Based (P)Rehabilitation Intervention with ExerciseRx in Muscle-Invasive Bladder Cancer”

Scope of the Award

The awarded projects focused on developing methods to reduce the burden of care and overtreatment for bladder cancer patients across the entire patient care continuum. Preference was given to studies that enrolled patients and proposed a translational Phase I or II clinical trial. In cases where a clinical trial was not proposed, applicants were required to justify how the study would lead to a clinical trial as the immediate next step or facilitate the translation of results into clinical practice. The studies were designed to support changes to the standard of care in bladder cancer, aiming to increase survival, decrease overtreatment, and improve patient quality of life.

Now that the award cycle has concluded, we maintain this page to inform visitors about the impactful research supported by the Translational Clinical Trial Award. Stay tuned for updates on future initiatives and opportunities.

More information

Learn more about the Bladder Cancer Advocacy Network’s research grant program as well as additional funding opportunities.

Read Our Stories